Meropenem Fresenius Kabi

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as an intravenous solution for intravenous use. It is employed to treat serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, meningitis, and septicemia in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare institutions. Clients benefit from consistent product availability, regulatory compliance, and dedicated technical support.

Meropenem is a carbapenem antibiotic used to treat severe infections caused by susceptible bacteria.

Complicated intra‑abdominal infections: provides rapid bacterial eradication in patients with severe intra‑abdominal sepsis. Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens, including multidrug‑resistant strains, in complicated cystitis and pyelonephritis. Hospital‑acquired pneumonia: achieves high lung tissue concentrations to treat ventilator‑associated and other nosocomial pneumonias, including Pseudomonas. Meningitis: penetrates the cerebrospinal fluid to eradicate bacterial meningitis, even in resistant cases, caused by susceptible organisms. Septicemia: delivers bactericidal activity in bloodstream infections, including Gram‑negative sepsis, supporting rapid clinical stabilization.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate nausea may occur during infusion. - Diarrhea: watery diarrhea is frequently reported. - Rash: transient skin rash or pruritus may develop. - Elevated liver enzymes: transient increases in ALT or AST may be observed. - Headache: mild headache may be reported.

Serious or Rare Side Effects: - Seizures: risk increases in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated colitis: may cause severe watery diarrhea and colitis. - Anaphylactic reaction: sudden hypersensitivity with respiratory distress, hypotension, and urticaria.

When using Meropenem, clinicians should observe several precautionary measures to ensure safety and efficacy.

- Renal function: assess and adjust dose in patients with impaired renal clearance. - Hypersensitivity: discontinue immediately if signs of allergic reaction such as rash or anaphylaxis appear. - Seizure risk: monitor closely in patients with a history of seizures or central nervous system disorders. - Valproic acid co‑administration: avoid concurrent use due to increased risk of seizures. - Concomitant nephrotoxic drugs: use caution when combined with other agents that may affect kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Valproic acid: concurrent use markedly increases the risk of seizures. - Cytotoxic chemotherapy agents: may enhance nephrotoxicity when combined. - Other carbapenems: simultaneous administration can lead to additive toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: combined use may increase risk of renal impairment. - Aminoglycosides: additive nephrotoxic potential requires monitoring of kidney function. - Anticoagulants (e.g., warfarin): may potentiate anticoagulant effect, necessitating INR monitoring.